IRadimed Corporation growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +14.8%
EBITDA: +31.6%
EBIT: +23.4%
EPS: +18.5%
Free cash flow: +72.2%
Operating cash flow: +11.2%

Forward estimates

Revenue: +12.4%
EBITDA: +22.6%
EPS: +17.7%

Three-year CAGR

Revenue: +16.3%
EBITDA: +22.2%
EBIT: +18.7%
Net income: +20.6%
EPS: +20.2%
Free cash flow: +28.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.